Patents by Inventor Joseph R. Bertino

Joseph R. Bertino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090227490
    Abstract: Aplidine and aplidine analogues are of use for the treatment of cancer, in particular in the treatment of leukemias and lymphomas, especially in combination therapies.
    Type: Application
    Filed: April 30, 2009
    Publication date: September 10, 2009
    Applicant: Pharma Mar, S.A.U.
    Inventors: Joseph R. Bertino, Debabrata Barnejee, Saydam Guray, Jose Jimeno, Glynn Thomas Faircloth
  • Patent number: 7576188
    Abstract: Aplidine and aplidine analogues are of use for the treatment of cancer, in particular in the treatment of leukemias and lymphomas, especially in combination therapies.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: August 18, 2009
    Assignee: Pharma Mar, S.A.U.
    Inventors: Joseph R. Bertino, Debabrata Barnejee, Saydam Guray, José Jimeno, Glynn Thomas Faircloth
  • Patent number: 7514413
    Abstract: This invention also provides a method for treating a cancer subject comprising administering to the subject a combination of ATP-depleting agents at concentrations which deplete the ATP level to, or close to, at least 15% of normal in cancer cells wherein at least one of the ATP-depleting agents is a mitochondrial ATP-inhibitor, a methylthioadenosine phosphorylase inhibitor or an inhibitor of De Novo purine synthesis other than 6-Methylmercaptopurine riboside, wherein said composition produces a substantially better effect than a composition without at least one of the ATP-depleting agents: a mitochondrial ATP-inhibitor, a glycolytic inhibitor, a methylthioadenosine phosphorylase inhibitor and an inhibitor of De Novo purine synthesis other than 6-Methylmercaptopurine riboside.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: April 7, 2009
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Daniel S. Martin, Joseph R. Bertino, Jason Koutcher
  • Patent number: 7381713
    Abstract: This invention provides a method for treating a cancer subject comprising administering to the subject a combination of ATP-depleting agents at concentrations which deplete the ATP level to at least 15% of normal in cancer cells, a pyrimidine antagonist, and an anticancer agent to which the treated cancer is sensitive. This invention also provides a composition comprising a combination of ATP-depleting agents at concentrations which deplete the ATP level to at least 15% of normal in cancer cells, a pyrimidine antagonist, and an anticancer agent to which the treated cancer is sensitive. Finally this invention provides a pharmaceutical composition comprising the above composition or a combination thereof and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: June 3, 2008
    Assignee: Sioan-Kettering Institute for Cancer Research
    Inventors: Daniel S. Martin, Joseph R. Bertino, Jason Koutcher
  • Patent number: 7381703
    Abstract: Aplidine and aplidine analogues are used in the manufacture of a medicament for treating multiple myeloma.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: June 3, 2008
    Assignees: Dana-Faber Cancer Institute, Inc., Pharma Mar, S.A.
    Inventors: Joseph R. Bertino, Daniel Medina, Glynn Thomas Faircloth, Constantine S. Mitsiades, Kenneth Anderson, Nicholas Mitsiades
  • Patent number: 6965034
    Abstract: The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof, useful in the treatment of cancer and cancer which has developed a multidrug-resistant phenotype. Also provided are intermediates useful for preparing said epothilones.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: November 15, 2005
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, Peter Bertinato, Dai-Shi Su, DongFang Meng, Ting-Chao Chou, Ted Kamenecka, Erik J Sorensen, Aaron Balog, Kenneth A. Savin, Scott Kuduk, Christina Harris, Xiu-Guo Zhang, Joseph R. Bertino
  • Patent number: 6887467
    Abstract: New mutant forms of human dihydrofolate reductase (DHFR) which have properties superior to the previously disclosed mutants have mutations at both amino acid 22 and amino acid 31. Specific mutant forms are Ser31Tyr22, Ser31Phe22, Gly31Tyr22, Gly31Phe22, Ala31Tyr22 and Ala31Phe22. The mutant DHFR of the invention may be used as a selectable marker, and to modify the genome of human cells, particularly bone marrow cells or peripheral blood stem cells, to render them resistant to chemotherapy using antifolate agents.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: May 3, 2005
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Joseph R. Bertino, Emine A. Ercikan-Abali, Debabrata Banerjee, Shin Mineishi, Michel Sadelain
  • Publication number: 20030208080
    Abstract: The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof, useful in the treatment of cancer and cancer which has developed a multidrug-resistant phenotype. Also provided are intermediates useful for preparing said epothilones.
    Type: Application
    Filed: December 23, 2002
    Publication date: November 6, 2003
    Inventors: Samuel J. Danishefsky, Peter Bertinato, Dai-Shi Su, DongFang Meng, Ting-Chao Chou, Ted Kamenecka, Erik J. Sorensen, Aaron Balog, Kenneth A. Savin, Scott Kuduk, Christina Harris, Xiu-Guo Zhang, Joseph R. Bertino
  • Patent number: 6642043
    Abstract: New mutant forms of human dihydrofolate reductase (DHFR) which have properties superior to the previously disclosed mutants have mutations at both amino acid 22 and amino acid 31. Specific mutant forms are Ser31Tyr22, Ser31Phe22, Gly31Tyr22, Gly31Phe22, Ala31Tyr22 and Ala31Phe22. The mutant DHFR of the invention maybe used as a selectable marker, and to modify the genome of human cells, particularly bone marrow cells or peripheral blood stem cells, to render them resistant to chemotherapy using antifolate agents.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: November 4, 2003
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Joseph R. Bertino, Emine A. Ercikan-Abali, Debabrata Banerjee, Shin Mineishi, Michel Sadelain
  • Patent number: 6603023
    Abstract: The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof, useful in the treatment of cancer and cancer which has developed a multidrug-resistant phenotype. Also provided are intermediates useful for preparing said epothilones.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: August 5, 2003
    Assignee: Sloan Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, Peter Bertinato, Dai-Shi Su, DongFang Meng, Ting-Chao Chou, Ted Kamenecka, Erik J. Sorensen, Aaron Balog, Kenneth A. Savin, Scott Kuduk, Christina Harris, Xiu-Guo Zhang, Joseph R. Bertino
  • Publication number: 20030139331
    Abstract: This invention provides a method for treating a cancer subject comprising administering to the subject a combination of ATP-depleting agents at concentrations which deplete the ATP level to at least 15% of normal in cancer cells, a pyrimidine antagonist, and an anticancer agent to which the treated cancer is sensitive. This invention also provides a composition comprising a combination of ATP-depleting agents at concentrations which deplete the ATP level to at least 15% of normal in cancer cells, a pyrimidine antagonist, and an anticancer agent to which the treated cancer is sensitive. Finally this invention provides a pharmaceutical composition comprising the above composition or a combination thereof and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 13, 2002
    Publication date: July 24, 2003
    Inventors: Daniel S. Martin, Joseph R. Bertino, Jason Koutcher
  • Publication number: 20030105330
    Abstract: The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof, useful in the treatment of cancer and cancer which has developed a multidrug-resistant phenotype. Also provided are intermediates useful for preparing said epothilones.
    Type: Application
    Filed: February 1, 2002
    Publication date: June 5, 2003
    Inventors: Samuel J. Danishefsky, Peter Bertinato, Dai-Shi Su, Dongfang Meng, Ting-Chao Chou, Ted Kamenecka, Erik J. Sorensen, Aaron Balog, Kenneth A. Savin, Scott Kuduk, Christina Harris, Xiu-Guo Zhang, Joseph R. Bertino
  • Publication number: 20030069277
    Abstract: The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof, useful in the treatment of cancer and cancer which has developed a multidrug-resistant phenotype. Also provided are intermediates useful for preparing said epothilones.
    Type: Application
    Filed: April 30, 2002
    Publication date: April 10, 2003
    Inventors: Samuel J. Danishefsky, Peter Bertinato, Dai-Shi Su, Dongfang Meng, Ting-Chao Chou, Ted Kamenecka, Erik J. Sorensen, Aaron Balog, Kenneth A. Savin, Scott Kuduk, Christina Harris, Xiu-Guo Zhang, Joseph R. Bertino
  • Patent number: 6416987
    Abstract: The present invention provides a mutated human TS, said mutated synthase differing from wild type TS at amino acid residue 49, amino acid residue 52, amino acid residue 108, amino acid residue 221 or amino acid residue 225. Also provided is cDNA mutated human TSs and novel vectors and host cells and methods of using the mutated human TSs.
    Type: Grant
    Filed: August 4, 1999
    Date of Patent: July 9, 2002
    Assignee: Sloan Kettering Institute for Cancer Research
    Inventors: Xinyue Liu-Chen, Youzhi Tong, Joseph R. Bertino, Debabrata Banerjee
  • Patent number: 6355639
    Abstract: The present invention provides a method for treating a subject in need of immunosuppression, comprising administering to the subject an effective amount of a compound having structure (I) wherein R1, R6 and R7 are independently hydrogen, OH, NH2, SH, halogen, C1-C9 linear or branched chain alkyl, alkylmercapto, alkylamino, etc.; wherein R0 and R2 are independently hydrogen, OH, C1-C9 linear or branched chain alkyl, —CR3R3—CH(O)CH2, —CR3R3—CH═CHR4, etc.; wherein R3 and R4 are independently hydrogen halogen C1-C9 linear or branched chain alkyl, etc.; wherein R5 is hydrogen, C1-C9 linear or branched chain alkyl, phenyl, alkylphenyl, dialkylphenyl, alkylmercapto, etc.; and wherein R8 is hydrogen, C1-C9 linear or branched chain acyl, benzoyl, alkylbenzoyl, etc. Also provided are methods of treating autoimmune disease and preventing organ graft rejection using N-acetylardeemin and related compounds.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: March 12, 2002
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ting-Chao Chou, Joseph R. Bertino, Samuel J. Danishefsky, Barry D. Kahan
  • Patent number: 6204388
    Abstract: The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof, useful in the treatment of cancer and cancer which has developed a multidrug-resistant phenotype. Also provided are intermediates useful for preparing said epothilones.
    Type: Grant
    Filed: February 24, 1999
    Date of Patent: March 20, 2001
    Assignee: Sloan-Kettering Institute For Cancer Research
    Inventors: Samuel J. Danishefsky, Peter Bertinato, Dai-Shi Su, DongFang Meng, Ting-Chao Chou, Ted Kamenecka, Erik J Sorensen, Aaron Balog, Kenneth A. Savin, Scott Kuduk, Christina Harris, Xiu-Guo Zhang, Joseph R. Bertino